Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients

Alcoholism: Clinical and Experimental Research

Volumn 33, Issue 2, 2009, Pages 350-356

  Pettinati, Helen M ^a   Gastfriend, David R ^b   Dong, Qunming ^b   Kranzler, Henry R ^c   O'Malley, Stephanie S ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ALKERMES INC   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol dependence; Extended release naltrexone; Heavy drinking; Naltrexone; Quality of life

Indexed keywords

NALTREXONE; PLACEBO;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION;

ADULT; ALCOHOL DRINKING; ALCOHOLISM; DELAYED-ACTION PREPARATIONS; EMPLOYMENT; ETHNIC GROUPS; FEMALE; HEALTH STATUS; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SOCIAL BEHAVIOR; SOCIAL SUPPORT;

EID: 58849121948     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2008.00843.x     Document Type: Article

References (38)

1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA 295 : 2003 2017.
2. Baros AM, Latham PK, Moak DH, Voronin K, Anton RF (2007) What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 31 : 596 603.
3. Bouza C, Angeles M, Munoz A, Amate JM (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99 : 811 828.
4. Daeppen JB, Krieg MA, Burnand B, Yersin B (1998) MOS-SF-36 in evaluating health-related quality of life in alcohol-dependent patients. Am J Drug Alcohol Abuse 24 : 685 694.
5. Donovan D, Mattson ME, Cisler RA, Longabaugh R, Zweben A (2005) Quality of life as an outcome measure in alcoholism treatment research. J Stud Alcohol Suppl 15 : 119 139.
6. Farivar SS, Liu H, Hays RD (2004) Half standard deviation estimate of the minimally important difference in HRQOL scores? Expert Rev Pharmacoeconomics Outcomes Res 4 : 515 523.
7. Feeney GFX, Connor JP, Young R, Tucker J, McPherson A (2004) Alcohol dependence: the impact of cognitive behaviour therapy with or without naltrexone on subjective health status. Aust N Z J Psychiatry 38 : 842 848.
8. Foster JH, Peters TJ, Marshall EJ (2000) Quality of life measures and outcome in alcohol-dependent men and women. Alcohol 22 : 45 52.
9. Foster JH, Powell JE, Marshall EJ, Peters TJ (1999) Quality of life in alcohol-dependent subjects - a review. Qual Life Res 8 : 255 261.
10. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C (2002) Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther 24 : 675 689.
11. Frone MR (2006) Prevalence and distribution of alcohol use and impairment in the workplace: a U.S. national survey. J Stud Alcohol 67 : 147 156.
12. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293 : 1617 1625.
13. Gastfriend D, Garbutt JC, Pettinati HM, Forman RF (2007) Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat 33 : 71 80.
14. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP (2004) The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 74 : 223 234.
15. Harris KM, Devries A, Dimidjian K (2004) Trends in naltrexone use among members of a large private health plan. Psychiatr Serv 55 : 221.
16. Hermos JA, Young MM, Gagnon DR, Fiore LD (2004) Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population. Alcohol Clin Exp Res 28 : 1229 1235.
17. Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ (2004) Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals. A randomized controlled trial. Arch Gen Psychiatry 61 : 905 912.
18. Johnson JG, Spitzer RL, Williams JBW, Kroenke K, Linzer M, Brody D, deGruy F, Hahn S (1995) Psychiatric comorbidity, health status, and functional impairment associated with alcohol abuse and dependence in primary care patients: findings of the PRIME MD-1000 Study. J Consul Clin Psychol 63 : 133 140.
19. Katschnig H, Freeman H, Sartorius N (2006) Quality of Life in Mental Disorders. 2nd ed. John Wiley & Sons, New York.
20. Kranzler HR, Stephenson JJ, Montejano L, Wang S, Gastfriend DR (2008) Persistence with oral naltrexone for alcohol treatment: implications for healthcare utilization. Addiction 103 : 1801 1808.
21. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med 345 : 1734 1739.
22. Liang KY, Zeger SL (1986) Longitudinal data analysis using general linear models. Biometrika 73 : 13 22.
23. Mark TL, Kranzler HR, Song X (2003) Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 71 : 219 228.
24. McGinnis JM, Foege WH (1999) Mortality and morbidity attributable to use of addictive substances in the United States. Proc Assoc Am Physicians 111 : 109 118.
25. Midanik LT, Tam T, Greenfield TK, Caetano R (1996) Risk functions for alcohol-related problems in a 1988 US national sample. Addiction 91 : 1427 1437.
26. Morgan MY, Landron F, Lehert P (2004) Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support. Alcohol Clin Exp Res 28 : 64 77.
27. Murray CJL, Lopez AD (1996) The Global Burden of Disease. World Health Organization. Harvard University Press, Cambridge, MA.
28. O'Malley S, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR (2007) Efficacy of extended-release naltrexone (XR-NTX) in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharm 27 : 507 512.
29. Pettinati HM, Volpicelli JR, Pierce JD Jr., O'Brien CP (2000) Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19 : 71 83.
30. Rehm J, Gmel G, Sempos CT, Trevisan M (2003) Alcohol-related morbidity and mortality. Alcohol Res Health 27 : 39 51.
31. Romeis JC, Waterman B, Scherrer JF, Goldberg J, Eisen SA, Heath AC, Bucholz KK, Slutske WS, Lyons MJ, Tsuang MT, True WR (1999) The impact of sociodemographics, comorbidity and symptom recency on health-related quality of life in alcoholics. J Stud Alcohol 60 : 653 662.
32. Room R, Babor T, Rehm J (2005) Alcohol and public health. Lancet 365 : 519 530.
33. Sobell L, Sobell M (1992) Timeline followback, a technique for assessing self-reported alcohol consumption, in : Measuring Alcohol Consumption (Allen LA ed pp 41 72. The Humana Press, Inc., Totowa, NJ.
34. Volk R, Cantor S, Steinbauer J, Cass A (1997) Alcohol use disorders, consumption patterns, and health-related quality of life of primary care patients. Alcohol Clin Exp Res 21 : 899 905.
35. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (2001) Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. Guilford Press, New York, NY.
36. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54 : 737 742.
37. Ware J, Kosinski M, Dewey J (2000) How to Score Version 2 of the SF-36 Health Survey. Quality Metric Incorporated, Lincoln, RI.
38. Weiss RD (2004) Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 99 : 1382 1392.